Let’s take a look back at how Halozyme, Roche, ImmunoGen, and Gilead Sciences achieved the three biggest medical advances of 2013.
In counting down our 12 Foolish Days of Christmas, we turn our attention to the 11 most important FDA approval of 2013. See which drugs could be ready to turn on the afterburners in 2014 and which patients can expect big improvements in quality of life.
Let’s take a look back at Immunomedics’ volatile performance throughout 2013 and see how it measures up to Seattle Genetics, ImmunoGen, and Roche -- companies that are also developing targeted cancer treatments.
8:30 am Immunogen announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR650984Briefing.com Dec 9
8:30 am Immunogen announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR650984
ImmunoGen, Inc. Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient PopulationBusiness Wire Dec 9
ImmunoGen, Inc. , a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate technology, today announced the presentation of clinical findings with SAR3419 used in combination with Rituxan® to treat diffuse large B-cell lymphoma that previously had been treated with standard therapies.
ImmunoGen, Inc. Announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR650984noodls Dec 9
Initial data from first clinical trial featured in oral presentation at American Society of Hematology (ASH) annual meeting; selected for "Best of ASH." Objective responses - including complete ...
Mylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 55th ASH Annual Meeting and Expositionnoodls Dec 3
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops targeted antibody-based anticancer therapeutics, today provided information on the clinical data presentations ...
Sarepta's huge drop leads a field of monthly losers that includes Aegerion's drop and Immunogen's plunge.
Stocks with insider trader activity include PM, PANW, IMGN, CYBX and IT
This obviously has been the first ADC, which now been approved for major solid tumor indication, the only ones that have shown survival advantage in the last randomized study. And obviously it gives, as ...
European Commission has approved Kadcyla® for marketing in the EU, which triggers a $5 million milestone payment to ImmunoGen. Kadcyla comprises Roche's trastuzumab antibody with ImmunoGen's linker and ...